Quellis Biosciences, Inc. — Form D/A
Quellis Biosciences, Inc. of WALTHAM, MA, a company, filed a Form D amendment with the SEC on 2020-08-18. The offering totals $18.5M, of which $12.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-08-18
- Form: D/A
- Accession: 0001741691-20-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $18.5M
- Amount sold: $12.1M
- Remaining: $6.5M
- Investors: 3
- Date of first sale: 2018-11-27
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-327586
Issuer
- Name: Quellis Biosciences, Inc.
- CIK: 0001741691
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 203 CRESCENT STREET, WALTHAM, MA, 02453
- Phone: 919-949-8552
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Tomas Kiselak | Director | West Conshohocken, PA |
| Tomas Kiselak | Executive Officer | West Conshohocken, PA |
| Peter Harwin | Director | West Conshohocken, PA |
| Peter Harwin | Executive Officer | West Conshohocken, PA |
| Chris Garabedian | Director | San Francisco, CA |
| Frederick Callori | Director | Philadephia, PA |
| Fred Callori | Director | Houston, TX |
| Jonathan Violin | Director | Waltham, MA |
| Jonathan Violin | Executive Officer | Waltham, MA |
| Christopher Garabedian | Director | Waltham, MA |
Other filings by this issuer (3)
More